Skip to main content
Tech.euFundingExplorerBeta

Alderaan Biotechnology

Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.

Alderaan Biotechnology has raised €19M across 1 funding round from 1 investor, most recently a Series A round in Jan 2020. Based in Paris, France; founded 2017; active in Healthtech. Data as of 28 Oct 2026.

Paris, FranceFounded 2017www.crunchbase.com/organization/alderaan-biotechnology ↗
Healthtech
← All companies
Total raised
€19M
€18,500,000
Funding rounds
1
Investors
1
distinct backers
Active since
2020-01
latest 2020-01

Funding by year

EUR raised per year
Alderaan Biotechnology — funding by year — interactive chart.
Data table
Alderaan Biotechnology — funding by year
2020€19M

Signals

High confidence
Raise-next likelihood8
base rate 44% for Series A
  • ▼ Dormant (no round in 3+ cohort gaps)
  • ▼ Low backer re-investment

Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

1 round
DateStageAmountInvestors
2020-01-09Series A€19MAdvent France Biotechnology (AFB) and MedicxiView deal →

Investors

1
Advent France Biotechnology (AFB) and Medicxi

Related news

Similar companies

same sector or country

Global coverage: FundingData